About
505(b)(2) for Neurodegenerative
Areas of Focus
Categories
NJ, NY, PA
Team (17)
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
79
By Phase
PHASE2: 3
By Status
ACTIVE_NOT_RECRUITING: 1UNKNOWN: 1COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT05218668Lead Sponsor
Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)
PHASE2Active, not recruiting
40 participants
Started: Dec 22, 2021 · Completed: Jan 31, 2029
NCT04734379Lead Sponsor
Rho Kinase (ROCK) Inhibitor in Tauopathies - 1
PHASE2Unknown
15 participants
Started: Jan 22, 2021 · Completed: Nov 30, 2023
NCT04793659Lead Sponsor
Fasudil fOr redUcing elopemeNt and Spatial Disorientation
PHASE2Completed
24 participants
Started: Dec 15, 2020 · Completed: Feb 11, 2022
Locations (1)
Headquarters
New York, NY, United States
Map
Loading map...